Please login to the form below

Not currently logged in
Email:
Password:

New leadership for Halozyme

Enzyme therapy developer Halozyme has appointed Gregory I Frost to serve as its new president and CEO, replacing Jonathan E Lim

Halozyme Therapeutics, the San Diego-based enzyme therapy developer that in October realigned its research priorities and cut its workforce by 25 per cent, has appointed Gregory I Frost to serve as its new president and CEO, effective immediately. He will replace Jonathan E Lim, who has resigned from the position as well as from his place on the board of directors "to pursue other opportunities."

Lim has led the company since 2003, while Frost has until now served as vice president, chief scientific officer.

In addition, H Michael Shepard, who recently joined the company as vice president of discovery research, has been promoted to chief scientific officer, while Robert J Little has resigned as vice president and chief commercial officer effective immediately.

Halozyme Therapeutics, whose partners include Roche and Baxter, is focused on researching the extracellular matrix for the endocrinology, oncology, dermatology and drug delivery markets. In October, the company said it would decreasing its research efforts on new drugs and cut 25 per cent of its workforce in order to concentrate its resources on "core proprietary programmes through key clinical inflection points in 2011 and 2012" and focus on the Baxter and Roche alliances.

However, the company said at the time that implementation of the strategy is not expected to impact previous net cash burn guidance and reiterated its guidance of $40m to $45m of net cash burn for 2010.

6th December 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Lucid Group Communications Limited

WE’RE ON A MISSION To enhance patients’ lives through communication that changes behaviour and improves patient health outcomes....

Latest intelligence

Ludovic Helfgott
Novo Nordisk awakens its ‘Sleeping Beauty’
Biopharm emerges from troubled times to hit ‘solid growth’, says executive vice president Ludovic Helfgott...
How will the Tories’ historic win shape the NHS?
Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore the impact of December’s General Election result on 2020 and beyond...
CSR 'Christmas Spirit' 2019
OPEN Health champions CSR over Christmas by giving back to the community and increasing our activities and efforts...

Infographics